Pittsburgh: A genetic test recently implemented at UPMC Presbyterian can
significantly reduce the risk of cardiovascular events by helping to
identify more effective medication for some heart patients, according to
the results of a large study conducted in part at the University of Pittsburgh and UPMC. The findings are being presented today at the American Heart Association’s Scientific Sessions in New Orleans.The test identifies a genetic deficiency that affects the body’s
ability to activate clopidogrel, a common anti-clotting drug given after
a coronary artery stent is inserted. About 30 percent of all patients
have the genetic deficiency, which can lead to decreased clopidogrel
effectiveness and increased risk for adverse cardiovascular events, such
as strokes, heart attacks and death.
